Skip to content

Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health

Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07801989
Acronym
AK ACE-PATH
Enrollment
360
Registered
2026-09-03
Start date
2026-09-21
Completion date
2029-04-30
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Health, Caridovascular Disease, Chronic Disease, Mental Health, Stress

Keywords

Alaska Native, rural health, prevention, chronic disease, extreme weather, community resilience

Brief summary

The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.

Detailed description

In Phase I of AK ACE, community partners identified and prioritized local stressors through a consensus-based process. Building on these findings, Phase II will implement interventions targeting the highest-priority stressors through modules designed to improve health outcomes.This study addresses a critical gap in understanding local health and mental health among AN populations facing rapid social change and overlapping public health challenges. The project focuses on developing community-driven solutions to improve physiological and mental health, particularly among youth, and to prevent chronic disease across the lifespan in rural Alaska. To achieve these goals, the study will develop and implement Tools for Arctic Health Promotion (TAHP), a novel intervention integrating data-driven tools and evidence-based community strategies. TAHP will support structured community engagement and deliver manualized health activities to approximately 410 adults and youth across five rural AN communities. The TAHP intervention will be evaluated through a feasibility pilot in one community and a paired dynamic waitlisted design (DWLD) across four additional communities. Behavioral and biological measures will assess individual- and community-level impacts on chronic disease prevention and mental health promotion.

Interventions

BEHAVIORALTools for Arctic Health Promotion

The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023). A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.

Sponsors

University of Alaska Fairbanks
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The study design to address the primary research questions will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3). As a variant of a stepped wedge group-randomized trial (SWGRT), the DWLD is a repeated measures, longitudinal intervention research design that makes use of an intervention implementation roll out crossover design. In the DWLD, each community receives both a baseline condition-essentially a wait-list control condition-and an intervention condition. In this study's implementation of the DWLD, the timing of crossover from baseline control to intervention condition is randomized.

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Self-identify as a permanent resident of the study community * Be a youth between the ages of 12-17 years or an adult 18+ * Be able to provide written informed consent

Exclusion criteria

* Does not have permanent residence in the community or has lived in the community less than 5 years * Is unable to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participationDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives. We will analyze how individual stress indicators are mitigated over time by intervention participation.
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participationDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction. We will assess how the intervention mitigates life satisfaction with individuals who participate.
We will assess if depression decreases with intervention participation using the PHQ-9 QuestionnaireDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks. We will assess how the intervention impacts depressive symptoms with individual participation.
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
We will assess if food security increases using the food security index from the PhenX ToolkitDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health. We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities. This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree." We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery ScaleDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions. It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks. We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness ScaleDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment. This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections. We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life ScaleDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people. It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide. We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.

Secondary

MeasureTime frameDescription
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community ScaleDay 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth. This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement. We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.

Countries

United States

Contacts

CONTACTStacy Rasmus, PhD
smrasmus@alaska.edu907-328-8919
CONTACTHannah Robinson, MPH
hrobinson3@alaska.edu731-400-3539

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026